Company: ENTXW
Filing Date: 2025-01-10
Form Type: 424B5
Source: 0001178913-25-000079
Chunk: 5

Company: Entera Bio Ltd.
Filing Date: 2025-01-10
Form: 424B5
Chunk 5
---
 anticipated in these forward-looking statements as a result of certain factors. Risks related to this offering and ownership of our ordinary shares The price of our ordinary shares may be volatile, and holders of our ordinary shares could lose all or part of their investment. The price of securities for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ordinary shares on Nasdaq may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:

| • | Our clinical trial results and the timing of the release of such results; |

| • | the amount of our cash resources and our ability to obtain additional funding; |

| • | announcements of research activities, business developments, technological innovations or new products, or acquisitions or expansion plans by us or our competitors; |

| • | success or failure of our research and development projects or those of our competitors; |

| • | our entering into or terminating strategic relationships; |

| • | changes in laws or government regulation; |

| • | actual or anticipated fluctuations in our and our competitors’ results of operations and financial condition; |

| • | regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products and plans for clinical development; |

| • | departure of our key personnel; |

| • | disputes related to intellectual property and proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies; |

| • | our sale, or the sale by our significant shareholders, of ordinary shares or other securities in the future; |

S - 3

| • | public concern regarding the safety, efficacy or other aspects of the products or methodologies we are developing; |

| • | market conditions in our industry and changes in estimates of the future size and growth rate of our markets; |

| • | market acceptance of our products; |

| • | the mix of products that we sell and related services that we provide; |

| • | the success or failure of our licensees to develop, obtain approval for and commercialize our licensed products, for which we are entitled to contingent payments and royalties; |

| • | publication of the results of preclinical or clinical trials for EB613, EB612 or any other product candidates we may develop; including the oral GLP-2 and OXM programs we are developing with OPKO Health, Inc. |

| • | failure